Hematopoietic stem cells for cancer immunotherapy
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Summary: Hematopoietic stem cells (HSC s) provide an attractive target for immunotherapy of cancer and leukemia by the introduction of genes encoding T‐cell receptors (TCR s) or chimeric antigen receptors (CAR s) directed against tumor‐associated antigens. HSC s engraft for long‐term blood cell production and could provide a continuous source of targeted anti‐cancer effector cells to sustain remissions. T cells produced de novo from HSC s may continuously replenish anti‐tumor T cells that have become anergic or exhausted from ex vivo expansion or exposure to the intratumoral microenvironment. In addition, transgenic T cells produced in vivo undergo allelic exclusion, preventing co‐expression of an endogenous TCR that could mis‐pair with the introduced TCR chains and blunt activity or even cause off‐target reactivity. CAR‐engineered HSC s may produce myeloid and natural killer cells in addition to T cells expressing the CAR, providing broader anti‐tumor activity that arises quickly after transplant and does not solely require de novo thymopoiesis. Use of TCR‐ or CAR‐engineered HSC s would likely require cytoreductive conditioning to achieve long‐term engraftment, and this approach may be used in clinical settings where autologous HSC transplant is being performed to add a graft‐versus‐tumor effect. Results of experimental and preclinical studies performed to date are reviewed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565 · cited 1×
“Although it is generally agreed that costimulation is required for efficacy in cancer immunotherapy approaches (4, 47, 56, 62, 63), to this moment it is still not fully resolved which costimulatory molecule produces the best results in CAR-mediated T-cell activation (nor for myeloid and NK cells).”
BackgroundChimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
Brentjens, R. J., Davila, M. L., Riviere, I., Park, J., Wang, X., Cowell, L. G., Bartido, S., Stefanski, J., Taylor, C., Olszewska, M., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005930 · Cited by 2,063
Kochenderfer, J. N., Wilson, W. H., Janik, J. E., Dudley, M. E., Stetler-Stevenson, M., Feldman, S. A., Maric, I., Raffeld, M., Nathan, D.-A. N., Lanier, B. J., et al. (2010) · Blood · doi:10.1182/blood-2010-04-281931 · Cited by 1,337
Milone, M. C., Fish, J. D., Carpenito, C., Carroll, R. G., Binder, G. K., Teachey, D., Samanta, M., Lakhal, M., Gloss, B., Danet-Desnoyers, G., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2009.83 · Cited by 1,197
Age, Thymopoiesis, and CD4+ T-Lymphocyte Regeneration after Intensive Chemotherapy
Mackall, C. L., Fleisher, T. A., Brown, M. R., Andrich, M. P., Chen, C. C., Feuerstein, I. M., Horowitz, M. E., Magrath, I. T., Shad, A. T., Steinberg, S. M., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199501193320303 · Cited by 1,026
Savoldo, B., Ramos, C. A., Liu, E., Mims, M. P., Keating, M. J., Carrum, G., Kamble, R. T., Bollard, C. M., Gee, A. P., Mei, Z., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci46110 · Cited by 1,023 · cited 1×
“Although it is generally agreed that costimulation is required for efficacy in cancer immunotherapy approaches (4, 47, 56, 62, 63), to this moment it is still not fully resolved which costimulatory molecule produces the best results in CAR-mediated T-cell activation (nor for myeloid and NK cells).”
BackgroundIsolation of Single Human Hematopoietic Stem Cells Capable of Long-Term Multilineage Engraftment
Notta, F., Doulatov, S., Laurenti, E., Poeppl, A., Jurisica, I., & Dick, J. E. (2011) · Science · doi:10.1126/science.1201219 · Cited by 919 · cited 1×
“Further enrichment of HSCs is an active area of research (19, 20) that will no doubt improve subsequent gene therapeutic approaches to immunotherapy.”
BackgroundHematopoiesis: a human perspective
Doulatov, S., Notta, F., Laurenti, E., & Dick, J. E. (2012) · Cell stem cell · doi:10.1016/j.stem.2012.01.006 · Cited by 895
Redesigning an FKBP–ligand interface to generate chemical dimerizers with novel specificity
Clackson, T., Yang, W., Rozamus, L. W., Hatada, M., Amara, J. F., Rollins, C. T., Stevenson, L. F., Magari, S. R., Wood, S. A., Courage, N. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.18.10437 · Cited by 558
Cited by
Stem Cells Applications in Regenerative Medicine and Disease Therapeutics
Mahla, R. S. (2016) · International Journal of Cell Biology · doi:10.1155/2016/6940283 · Cited by 604
Biasco, L., Pellin, D., Scala, S., Dionisio, F., Basso-Ricci, L., Leonardelli, L., Scaramuzza, S., Baricordi, C., Ferrua, F., Cicalese, M. P., et al. (2016) · Cell stem cell · doi:10.1016/j.stem.2016.04.016 · Cited by 243
Stem cells in cancer therapy: opportunities and challenges
Zhang, C.-L., Huang, T., Wu, B.-L., He, W.-X., & Liu, D. (2017) · Oncotarget · doi:10.18632/oncotarget.20798 · Cited by 203
“Introducing genes encoding chimeric antigen receptors (CARs) or T-cell receptors (TCRs) directed against tumor-associated antigens makes HSCs attractive for use in cancer immunotherapy [50, 51].”
BackgroundChimeric antigen receptor-engineered natural killer cells for cancer immunotherapy
Yilmaz, A., Cui, H., Caligiuri, M. A., & Yu, J. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00998-9 · Cited by 171
Adoptive T-cell therapy for cancer: the era of engineered T cells
Bonini, C., & Mondino, A. (2015) · European Journal of Immunology · doi:10.1002/eji.201545552 · Cited by 93
Metadata
- Authors
- Gschweng, E., De Oliveira, S., & Kohn, D. B.
- Venue
- Immunological Reviews
- Publisher
- Wiley
- Published
- 2013-12-13
- Volume
- 257
- Issue
- 1
- Pages
- 237-249
- ISSN
- 0105-2896 (ISSN-L)
- 1600-065X
- OpenAlex
- W2030445837
- Cited by
- 89
- References
- 10
- FWCI
- 0.81
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.